These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35211194)

  • 1. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC).
    Kashyap L; Patil V; Noronha V; Joshi A; Menon N; Jobanputra K; Saha S; Chaturvedi P; Banavali SD; Prabhash K
    Ecancermedicalscience; 2021; 15():1325. PubMed ID: 35211194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.
    Dessai SB; Chakraborty S; Babu TV; Nayanar S; Bhattacharjee A; Jones J; Balasubramanian S; Patil VM
    South Asian J Cancer; 2016; 5(2):63-6. PubMed ID: 27275450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
    McCormack M; Kadalayil L; Hackshaw A; Hall-Craggs MA; Symonds RP; Warwick V; Simonds H; Fernando I; Hammond M; James L; Feeney A; Ledermann JA
    Br J Cancer; 2013 Jun; 108(12):2464-9. PubMed ID: 23695016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center.
    Patil VM; Chakraborty S; Shenoy PK; Manuprasad A; Sajith Babu TP; Shivkumar T; Babu S; Bhatterjee A; Balasubramanian S
    Indian J Cancer; 2014; 51(1):69-72. PubMed ID: 24947100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for Stage IB2-IIB cervical cancer.
    Yang L; Guo J; Shen Y; Cai J; Xiong Z; Dong W; Min J; Wang Z
    Int J Clin Exp Med; 2015; 8(8):13690-8. PubMed ID: 26550314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial.
    Mittal A; Malik PS; Kumar S; Saikia J; Chitikela S; Khurana S; Bharti S; Jain D; Pathy S; Thulkar S; Kumar R; Madan K; Mohan A
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e553-e560. PubMed ID: 34340919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
    Rivkin SE; Moon J; Iriarte DS; Bailey E; Sloan HL; Goodman GE; BonDurant AE; Velijovich D; Wahl T; Jiang P; Shah CA; Drescher C; Fer MF; Kaplan HG; Ellis ED
    Int J Gynecol Cancer; 2019 Feb; 29(2):325-333. PubMed ID: 30700568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers.
    Patil VM; Prabhash K; Noronha V; Joshi A; Muddu V; Dhumal S; Arya S; Juvekar S; Chaturvedi P; Chaukar D; Pai P; Kane S; Patil A; Agarwal JP; Ghosh-Lashkar S; Dcruz A
    Oral Oncol; 2014 Oct; 50(10):1000-4. PubMed ID: 25130412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
    Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
    Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.
    Angioli R; Plotti F; Luvero D; Aloisi A; Guzzo F; Capriglione S; Terranova C; De Cicco Nardone C; Benedetti-Panici P
    Tumour Biol; 2014 Mar; 35(3):2741-6. PubMed ID: 24234333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy.
    Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Arya S; Juvekar S; Pai P; Chatturvedi P; Devendra AC; Ghosh S; D'cruz A; Kumar P
    Indian J Cancer; 2014; 51(1):20-4. PubMed ID: 24947091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitive Surgery after Neoadjuvant Chemotherapy for Locally Advanced Oral Cavity Cancers: Experience from a Tertiary Care Center.
    Agrawal M; Konduru V; Riju J; Singh A; Joel A; Karuppusami R; Tirkey AJ
    South Asian J Cancer; 2023 Oct; 12(4):341-348. PubMed ID: 38130286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.
    Dessai SB; Chakraborty S; Babu T; Nayanar S; Bhattacharjee A; Jones J; Balasubramanian S; Patil VM
    Indian J Cancer; 2016; 53(2):280-283. PubMed ID: 28071627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Metronomic Chemotherapy in Advanced and Metastatic Oral Squamous Cell Carcinoma: A Need of the Hour.
    Kumar NAN; Dikhit PS; Jose A; Mehta V; Pai A; Kudva A; Rao M
    J Maxillofac Oral Surg; 2024 Aug; 23(4):793-800. PubMed ID: 39118899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.